Currently there are no published patents or studies specifically describing small molecule antagonists of the chemokine receptor CCR6. CCL20 (MIP-3 alpha) is the endogenous peptide ligand for the G-protein coupled receptor (GPCR) CCR6. The receptor ligand pair is responsible for the chemoattraction of immature dendritic cells, effector/memory T cells, B cells, and also plays a role at skin and mucosal surfaces. The CCR6 receptor is expressed by B cells, subsets of T cells, and dendritic cells (DC). The link between the CCR6lCCL20 axis and cancer cell metastasis is a recent finding. There are two key studies that describe a relation between CCR6 and colorectal liver metastasis. The association between CCR6 expression levels in 64 primary tumor specimens in primary CRC and synchronous liver metastases suggests that CCR6 and CCL20 are involved in the metastatic spread to the liver.  A small molecule tool would address a key hypothesis: Modulation of the CCR6/CCL20 axis will regulate pathogenic activities of B cells in a variety of diseases including hematopoietic malignancy and cancer metastasis. The project goal is to identify a chemical probe of CCR6 receptor that can specifically act as 'chemical modulator' of CCR6 through inhibition (antagonism) of functional response. An important objective of this research program is to provide new insight into the regulation of cancer metastasis modulated by the CCR6/CCL20 (MIP-3 alpha) axis. In this assay we utilize enzyme-fragment complementation to directly measure GPCR activation. Unlike imaging or other second messenger assays, the DiscoveRx b-Arrestin assay allows for a direct measure of GPCR activation by detection of b-Arrestin binding to the CCR6 receptor. In this system, b-Arrestin is fused to an N-terminal deletion mutant of b-gal (termed the enzyme acceptor of EA) and the GPCR of interest is fused to a smaller (42 amino acids), weakly complementing fragment termed ProLink. In cells that stably express these fusion proteins, ligand stimulation results in the interaction of b-Arrestin and the Prolink-tagged GPCR, forcing the complementation of the two b-gal fragments and resulting in the formation of a functional enzyme that converts substrate to detectable signal. Antagonists would be expected to inhibit agonist activation of the receptor resulting in the inhibition of signal formation in this assay. The goal of this assay is to validate hits obtained in "uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay", AID 493098 and to study the structure-activity relationship on analogs of the confirmed hits. Compounds are either acquired from commercial sources or synthesized internally. A. Brief Description of the Assay: The purpose of this assay is to detect antagonists that inhibit the activation of the CCR6 receptor in the CHO-K1 beta-Arrestin Cell Line in 1536-well plate format in uHTS mode. B. Materials: PathHunter CHO-K1 CCR6 b-arrestin cell line (DiscoveRx, Cat# 93-0194C2) F12 nutrient mix HAMs (Invitrogen, Cat# 11765) Fetal Bovine Serum, heat-inactivated (Hyclone, Cat# SH30396) 100X Penicillin/Streptomycin Solution (Invitrogen, Cat#15140-122) Hygromycin B (Roche, Cat# 10843555001) Geneticin (MPBiomedicals, Cat # 1672548) Trypsin-EDTA 0.25% (Invitrogen, Cat# 25200-056) Cell Dissociation Buffer (Invitrogen, Cat# 13151) DPBS (Hyclone, Cat# 30028.02) T225 TC Flask (Nunc, Cat# 159934) 1536-well, white, solid-bottom, Kalypsys compatible, TC plate (Aurora) MIP-3a/CCL20 peptide (R&D Systems, Cat# 360MP) PathHunter Detection Reagents (DiscoveRx, Cat# 93-0001) Galacton Star Emerald 11 Cell Assay Buffer C. uHTS Procedures: Day1 Cell Seeding 1) Plate 800 cells/well in 4 uL of assay media into columns 1-48 of a 1536-well assay plate, using Biotek dispenser. 2) Centrifuge plates at 500 rpm for 1 minute on a Vspin centrifuge. Use Kalypsys metal lids. 3) Incubate overnight at 37 degrees, 100% relative humidity, 5% CO2 for 16-18 hours. Day2 Compound Addition 1) Centrifuge compound plates at 500 rpm for 1 minute on a Vspin centrifuge. 2) Using LabCyte Echo 555, transfer 40 nL of DMSO to positive and negative control wells in columns 1 - 4 and 45-48, respectively. Using a dose response protocol, transfer compounds from 10mM and 0.312 mM Echo qualified plates into assay plate columns 5 - 45. (Final concentrations range 66 uM to 0.128 uM, 10 doses, with 0.66% DMSO.) 3) Immediately following compound/DMSO transfer via the Echo, using the Biotek Dispenser, transfer 2ul/well of Assay media to Col. 1-2 for the positive control wells. 4) Using the Biotek Dispenser, add 2ul/well of 42 nM MIP3a/CCL20 (FAC = 14 nM) in assay media to Col. 3-48 for the negative control and test compound wells. 5) Centrifuge plates at 500 rpm for 1 minute on a Vspin centrifuge. 6) Incubate plates at 25 degrees in the dark for 90 minutes. 7) Following 90 minute incubation, deliver 3.0 uL of Detection Reagent solution to each assay plate (Columns 1 - 48) using a Biotek dispenser. 8) Centrifuge plates at 2000 rpm for 2 minute on a Vspin centrifuge. 9) Incubate plates for 60 minutes at 25 degrees in the dark. 10) Read plates using the Envision using a luminescence protocol. D. Recipes: Growth Media F12 nutrient mix HAMs supplemented with 10% hi-FBS, 1X Penicillin/Streptomycin; selection reagents: 300ug/ml Hygromycin B, 800ug/ml Geneticin Assay Media/Positive Control Same as Growth Media without the selection reagents and only 2.5% hi-FBS Trypsin Dilute 0.25% Trypsin/EDTA to 0.05% Trypsin/EDTA using DPBS Negative Control Growth Media with 14 nM MIP3a/CCL20 Detection Reagent Use the following ratio to prepare the detection reagent: Galacton Star : Emerald II : Assay Buffer = 1 : 5 : 19
bao:BAO_0000540 "493098" ; # "is confirmatory assay of" -> "493098"
bao:BAO_0000812 "493121" ; # "has summary assay" -> "493121"
bao:BAO_0000812 "493159" ; # "has summary assay" -> "493159"
bao:BAO_0000809 bao:BAO_0000030 ; # "has confirmatory assay" -> "confirmatory assay"
bao:BAO_0000205 bao:BAO_0000219 ; # "has assay format" -> "cell-based format"
bao:BAO_0000409 bao:BAO_0000410 ; # "assay measurement type" -> "endpoint assay"
bao:BAO_0002850 bao:BAO_0000534 ; # "has assay readout content" -> "single readout"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BA0_0090012 bao:BAO_0000284 ; # "has participant" -> "G protein coupled receptor" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0002855 bao:BAO_0200056 ; # "is bioassay type of" -> "beta galactosidase reporter gene assay"
bao:BAO_0000212 bao:BAO_0000123 ; # "has assay method" -> "binding assessment method"
bao:BAO_0000212 bao:BAO_0000406 ; # "has assay method" -> "protein fragment complementation method"
bao:BAO_0000207 bao:BAO_0000051 ; # "has detection method" -> "chemiluminescence"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "\"Antagonists of the chemokine C-C motif receptor 6, CCR6\"" ; # "screening campaign name" -> ""Antagonists of the chemokine C-C motif receptor 6, CCR6""
bao:BAO_0002853 "SAR analysis of small molecule antagonists of the CCR6 receptor: a luminescent beta-arrestin assay." ; # "has assay title" -> "SAR analysis of small molecule antagonists of the CCR6 receptor: a luminescent beta-arrestin assay."
bao:BAO_0002854 bao:BAO_0000010 ; # "has bioassay type" -> "functional"
bao:BAO_0002867 bao:BAO_0000516 ; # "has assay footprint" -> "1536 well plate"
bao:BAO_0002863 bao:BAO_0000535 ; # "has concentration throughput" -> "multiple concentration"
bao:BAO_0000109 "25 degree celsius" ; # "has temperature value" -> "25 degree celsius"
bao:BAO_0002833 "90 minute" ; # "has incubation time value" -> "90 minute"
bao:BA0_0090012 "\"DMSO, assay media\"" ; # "has participant" -> ""DMSO, assay media""
bao:BAO_0000740 bao:BAO_0000080 ; # "has assay control" -> "positive control"
bao:BA0_0090012 "MIP3a/CCL20 peptide 14 nanomolar" ; # "has participant" -> "MIP3a/CCL20 peptide 14 nanomolar"
bao:BAO_0000740 bao:BAO_0000079 ; # "has assay control" -> "negative control"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Greg Roth" ; # "material entity assay provider" -> "Greg Roth" || bao:BAO_0003102 bao:BAO_0000027 ; # "has role" -> "assay provider"
bao:BAO_0002020 bao:BAO_0000373 ; # "has assay phase characteristic" -> "heterogeneous phase"
bao:BAO_0000118 "0.66%" ; # "DMSO" -> "0.66%"
bao:BAO_0002000 bao:BAO_0000963 ; # "has measured entity" -> "Macrophage inflammatory protein 3 alpha" || bao:BAO_0003102 bao:BAO_00020138 ; # "has role" -> "potentiator"
bao:BA0_0090012 "C-C chemokine receptor type 6" ; # "has participant" -> "C-C chemokine receptor type 6"
bao:BAO_0002004 <http://purl.obolibrary.org/obo/CLO_0002462> ; # "has cell line" -> "CHO-K1 cell"
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_9606> ; # "has organism" -> "Homo sapiens"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "1235" ; # "gene ID" -> "1235"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "P51684" ; # "uniprot ID" -> "P51684"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "9606" ; # "NCBI taxonomy ID" -> "9606"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "10% heat inactivated fetal bovine serum" ; # "material entity culture serum" -> "10% heat inactivated fetal bovine serum" || bao:BAO_0003102 bao:BAO_0002596 ; # "has role" -> "culture serum"
bao:BAO_0002922 "\"F12 HAMs 2.5% hi-FBS, 1X Penicillin/Streptomycin, 300ug/ml Hygromycin B, 800 ug/ml Geneticin\"" ; # "has assay medium" -> ""F12 HAMs 2.5% hi-FBS, 1X Penicillin/Streptomycin, 300ug/ml Hygromycin B, 800 ug/ml Geneticin""
bao:BAO_0002922 bao:BAO_0000596 ; # "has assay medium" -> "assay medium"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "2.5% heat inactivate fetal bovine serum" ; # "material entity assay serum" -> "2.5% heat inactivate fetal bovine serum"
bao:BAO_0002923 bao:BAO_0002597 ; # "has assay serum" -> "assay serum"
bao:BAO_0000212 bao:BAO_0000246 ; # "has assay method" -> "stable transfection"
bao:BAO_0000550 "Expressing ProLink/Enzyme Donor (PK)-tagged CCR6 and the Enzyme Activator (EA)-tagged ?-Arrestin fusion proteins" ; # "DNA construct" -> "Expressing ProLink/Enzyme Donor (PK)-tagged CCR6 and the Enzyme Activator (EA)-tagged ?-Arrestin fusion proteins"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "1235" ; # "construct gene ID" -> "1235"
bao:BAO_0002662 bao:BAO_0002157 ; # "has quality" -> "native form"
bao:BAO_0002897 bao:BAO_0000360 ; # "has preparation method" -> "recombinant expression"
bao:BA0_0090012 bao:BAO_0000750 ; # "has participant" -> "Beta-galactosidase"
bao:BAO_0002000 bao:BAO_0002001 ; # "has measured entity" -> "measured entity"
bao:BAO_0002857 bao:BAO_0000261 ; # "has signal direction" -> "signal decrease corresponding to inhibition"
bao:BAO_0000308 bao:BAO_0000988 ; # "has assay kit" -> "PathHunter Beta-Arrestin Assay"
bao:BAO_0000308 bao:BAO_0000248 ; # "has assay kit" -> "assay Kit"
bao:BAO_0000737 bao:BAO_0000893 ; # "has manufacturer" -> "DiscoveRx" || bao:BAO_0003102 bao:BAO_0002626 ; # "has role" -> "biologics and screening manufacturer"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0002865 bao:BAO_0000701 ; # "uses detection instrument" -> "EnVision Multilabel Reader"
bao:BAO_0000737 bao:BAO_0000297 ; # "has manufacturer" -> "Perkin Elmer" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0000208 bao:BAO_0000190 ; # "has endpoint" -> "IC50"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "2" ; # "PubChem TID" -> "2"
bao:BAO_0002787 "10" ; # "has concentration-point number" -> "10"
bao:BAO_0002845 "4" ; # "has repetition point-number" -> "4"
bao:BAO_0000196 bao:BAO_0000441 ; # "has mode of action" -> "competitive binding"
bao:BAO_0002864 bao:BAO_0000533 ; # "has repetition throughput" -> "multiple repetition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "mp" ; # "Annotated by" -> "mp"
